Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2Phase EARLY_PHASE1 1Phase 4 1Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Letrozole 6Cisplatin 5Tamoxifen 4Carboplatin 4Anastrozole 4ribociclib 3exemestane 3atezolizumab 3Vancomycin 3Specimen Handling 3Nivolumab 3Magnetic Resonance Spectroscopy 3Human Papillomavirus Recombinant Vaccine nonavalent 3Dexamethasone 3Bevacizumab 3trametinib 2toripalimab 2relatlimab 2pembrolizumab 2encorafenib 2dabrafenib 2binimetinib 2asciminib 2Vincristine 2Sodium Chloride 2Rituximab 2Prednisone 2Papillomavirus Vaccines 2Methotrexate 2Medroxyprogesterone Acetate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × fluciclovine F-18 × 90 days × Clear all
NCT07569926 2026-06-02

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

Blue Earth Diagnostics

Phase 4 Not yet recruiting
142 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡